22 min listen
Cell and Gene Therapy Investment Trends
Cell and Gene Therapy Investment Trends
ratings:
Length:
20 minutes
Released:
Nov 22, 2021
Format:
Podcast episode
Description
Cell and gene therapies are currently among the hottest investments in the biotech space, both in the public and private markets. In this episode, Back Bay’s Managing Director and host Pete Bak, PhD is joined by Kyle O’Neil and Brendan Wang, who are returning to the podcast after attending the 2021 Cell and Gene Meeting on the Mesa. Tune in to hear their discussion on emerging investment themes and which ones were key topics of discussion at this year’s conference.Topics include:
The next generation of gene-editing technology
CRISPR 2.0
Off-target effects
Novel nucleases
PAM sequences
Autologous and Allogeneic CAR-T cell therapy
Ex vivo vs. in vivo approaches
The business model on gene therapies
Figuring out manufacturing capabilities first
How to tap into larger markets
Building businesses around small monogenic diseases
Learn more, read Bay Life Science Advisors' latest white paper on gene therapy innovation here.Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn.Thank you for joining us.
The next generation of gene-editing technology
CRISPR 2.0
Off-target effects
Novel nucleases
PAM sequences
Autologous and Allogeneic CAR-T cell therapy
Ex vivo vs. in vivo approaches
The business model on gene therapies
Figuring out manufacturing capabilities first
How to tap into larger markets
Building businesses around small monogenic diseases
Learn more, read Bay Life Science Advisors' latest white paper on gene therapy innovation here.Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn.Thank you for joining us.
Released:
Nov 22, 2021
Format:
Podcast episode
Titles in the series (27)
Gene Therapies: What’s to Come as The Industry Moves Forward: In this episode our host, Dr. Peter Bak, sits down with Brendan Wang and Kyle O’Neil of Back Bay Life Science Advisors to discuss the field of gene therapies and insights from their recently authored piece in Cell & Gene, “The Next Decade In Gene Therapy by Back Bay Life Science Report